A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design

被引:23
作者
Thorsen, Lene [1 ]
Nilsen, Tormod S. [2 ]
Raastad, Truls [2 ]
Courneya, Kerry S. [3 ]
Skovlund, Eva [4 ,5 ]
Fossa, Sophie D. [1 ]
机构
[1] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[2] Norwegian Sch Sports Sci, Dept Phys Performance, Oslo, Norway
[3] Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB, Canada
[4] Norwegian Inst Publ Hlth, Oslo, Norway
[5] Univ Oslo, Sch Pharm, Oslo, Norway
关键词
Strength training; Prostate cancer; Androgen deprivation therapy; Clinical and muscle cellular outcomes; BONE-MINERAL DENSITY; PHYSICAL-ACTIVITY TRIALS; QUALITY-OF-LIFE; LEAN BODY-MASS; SKELETAL-MUSCLE; SATELLITE CELLS; RESISTANCE EXERCISE; MEN; TESTOSTERONE; HYPERTROPHY;
D O I
10.1186/1471-2407-12-123
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies indicate that strength training has beneficial effects on clinical health outcomes in prostate cancer patients during androgen deprivation therapy. However, randomized controlled trials are needed to scientifically determine the effectiveness of strength training on the muscle cell level. Furthermore, close examination of the feasibility of a high-load strength training program is warranted. The Physical Exercise and Prostate Cancer (PEPC) trial is designed to determine the effectiveness of strength training on clinical and muscle cellular outcomes in non-metastatic prostate cancer patients after high-dose radiotherapy and during ongoing androgen deprivation therapy. Methods/design: Patients receiving androgen deprivation therapy for 9-36 months combined with external high-dose radiotherapy for locally advanced prostate cancer are randomized to an exercise intervention group that receives a 16 week high-load strength training program or a control group that is encouraged to maintain their habitual activity level. In both arms, androgen deprivation therapy is continued until the end of the intervention period. Clinical outcomes are body composition (lean body mass, bone mineral density and fat mass) measured by Dual-energy X-ray Absorptiometry, serological outcomes, physical functioning (muscle strength and cardio-respiratory fitness) assessed with physical tests and psycho-social functioning (mental health, fatigue and health-related quality of life) assessed by questionnaires. Muscle cellular outcomes are a) muscle fiber size b) regulators of muscle fiber size (number of myonuclei per muscle fiber, number of satellite cells per muscle fiber, number of satellite cells and myonuclei positive for androgen receptors and proteins involved in muscle protein degradation and muscle hypertrophy) and c) regulators of muscle fiber function such as proteins involved in cellular stress and mitochondrial function. Muscle cellular outcomes are measured on muscle cross sections and muscle homogenate from muscle biopsies obtained from muscle vastus lateralis. Discussion: The findings from the PEPC trial will provide new knowledge on the effects of high-load strength training on clinical and muscle cellular outcomes in prostate cancer patients during androgen deprivation therapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy
    Shabbir M. H. Alibhai
    Daniel Santa Mina
    Paul Ritvo
    George Tomlinson
    Catherine Sabiston
    Murray Krahn
    Sara Durbano
    Andrew Matthew
    Padraig Warde
    Meagan O’Neill
    Narhari Timilshina
    Roanne Segal
    Nicole Culos-Reed
    BMC Cancer, 19
  • [22] Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
    Brian D. Gonzalez
    Heather S. L. Jim
    Brent J. Small
    Steven K. Sutton
    Mayer N. Fishman
    Babu Zachariah
    Randy V. Heysek
    Paul B. Jacobsen
    Supportive Care in Cancer, 2016, 24 : 2201 - 2207
  • [23] Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer
    Taaffe, Dennis R.
    Buffart, Laurien M.
    Newton, Robert U.
    Spry, Nigel
    Denham, James
    Joseph, David
    Lamb, David
    Chambers, Suzanne K.
    Galvao, Daniel A.
    BJU INTERNATIONAL, 2018, 121 (02) : 194 - 202
  • [24] Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
    Gonzalez, Brian D.
    Jim, Heather S. L.
    Small, Brent J.
    Sutton, Steven K.
    Fishman, Mayer N.
    Zachariah, Babu
    Heysek, Randy V.
    Jacobsen, Paul B.
    SUPPORTIVE CARE IN CANCER, 2016, 24 (05) : 2201 - 2207
  • [25] A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy
    Kiwata, Jacqueline L.
    Dorff, Tanya B.
    Schroeder, E. Todd
    Salem, George J.
    Lane, Christianne J.
    Rice, Judd C.
    Gross, Mitchell E.
    Dieli-Conwright, Christina M.
    BMJ OPEN, 2017, 7 (07):
  • [26] Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial
    Cormie, Prue
    Galvao, Daniel A.
    Spry, Nigel
    Joseph, David
    Chee, Raphael
    Taaffe, Dennis R.
    Chambers, Suzanne K.
    Newton, Robert U.
    BJU INTERNATIONAL, 2015, 115 (02) : 256 - 266
  • [27] Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer
    Chiang, Pai-Kai
    Tsai, Wei-Kung
    Chiu, Allen Wen-Hsiang
    Lin, Jhen-Bin
    Yang, Feng-Yi
    Lee, Jie
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [28] Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial
    Dai, Bo
    Zhang, Sheng
    Wan, Fang-Ning
    Wang, Hong-Kai
    Zhang, Jun -Yu
    Wang, Qi-Feng
    Kong, Yun-Yi
    Ma, Xue-Jun
    Mo, Miao
    Zhu, Yao
    Qin, Xiao-Jian
    Lin, Guo-Wen
    Ye, Ding -Wei
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 519 - 525
  • [29] Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial
    Ndjavera, Wilphard
    Orange, Samuel T.
    O'Doherty, Alasdair F.
    Leicht, Anthony S.
    Rochester, Mark
    Mills, Robert
    Saxton, John M.
    BJU INTERNATIONAL, 2020, 125 (01) : 28 - 37
  • [30] Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer
    Huang, Yuan-Bin
    Li, Wei-Lin
    Sun, Man
    Duan, Xu
    Wang, Yu-Tong
    Zhang, Lu-Xin
    Xin, Zi-Han
    Yun, Zhi-Fei
    Fan, Bo
    Li, Xian-Cheng
    ASIAN JOURNAL OF ANDROLOGY, 2023, 25 (03) : 366 - 374